Researchers

KUDO Masatoshi

KUDO Masatoshi
Professor/Senior Staff/Vice President
Faculty Department of Medicine / Graduate School of Medical Sciences
Researchmap https://researchmap.jp/m-kudo

Education and Career

Academic & Professional Experience

  • Apr. 1999 - Today , Kindai University Faculty of Medicine Professor and Chairman

Research Activities

Research Areas

  • Life sciences , Medical systems
  • Life sciences , Gastroenterology
  • Life sciences , Tumor diagnostics and therapeutics

Research Interests

Hepatocellular carcinoma, 肝腫瘍の画像診断, Conrast-ehnaced ultrasonogaraphy, EOB-MRI, Radiofreuqency ablation (RFA), Transarterial chemoembolization (TACE), 肝動注化学療法, Molecular targeted therapy, 血管新生阻害治療, Immunotherapy, Immune checkpoint inhibitor

Published Papers

  1. Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.
    Maria Qurashi; Maria Buti; Grace Lai-Hung Wong; Huma Qureshi; Masatoshi Kudo; Tawesak Tanwandee; Chien-Jen Chen; Ashraf Omar Abdelaziz; Mohamed AbdAllah; Jessica Howell; Vanessa Hebditch; Amit G Singal; Peter Jepsen; Rohini Sharma
    The Lancet regional health. Europe  70  , 101852-101852, Nov. 2026 
  2. Prognostic role of the Child-Turcotte-Pugh classification and ALBI grade in patients without cirrhosis and hepatocellular carcinoma.
    Lorenz Balcar; Leonardo Brunetti; Katharina Pomej; Abelina Kreuter; Claudia Angela Maria Fulgenzi; Ahmer Adnan; Tobias Meischl; Antonio D'Alessio; Giulia Manfredi; Hong Jae Chon; Naoshi Nishida; Pei-Chang Lee; Celina Ang; Anja Krall; Najib Ben Khaled; Bernardo Stefanini; Tiziana Pressiani; Joe Ramzi Eid; Anwar Saeed; Alessandro Parisi; Yi-Hsiang Huang; Ashwini Arvind; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Natascha Röhlen; Arndt Vogel; Kornelius Schulze; Johann von Felden; Marianna Silletta; Michael Trauner; Ilario Giovanni Rapposelli; Henning Wege; Fabio Piscaglia; Peter R Galle; Rudolf Stauber; Masatoshi Kudo; Amit G Singal; Susanna V Ulahannan; Haripriya Andanamala; Andrea Casadei-Gardini; Iakow Bolnykh; Sarah Mouri; Charles Roux; Ahmed Kaseb; Lorenza Rimassa; Beodeul Kang; Ciro Celsa; Michael Li; Mario Pirisi; Calogero Cammà; Giuseppe Cabibbo; Eleonora Alimenti; Massimo Iavarone; Pasquale Lombardi; Robin Kate Kelley; Marta Fortuny; Maria Reig; Andrea Dalbeni; Hidenori Toyoda; Wei-Fan Hsu; Chun-Yen Lin; Po Ting Lin; Bernhard Scheiner; Manon Allaire; David J Pinato; Matthias Pinter
    JHEP reports : innovation in hepatology  , 102053-102053, 30, Sep. 2026 
  3. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.
    Jaclyn Neely; Jin Yao; Masatoshi Kudo; Richard S Finn; Bruno Sangro; Ignacio Melero; Anthony B El-Khoueiry; Thomas Yau; James J Harding; Olivier Rosmorduc; Marina Tschaika; Ruslan Novosiadly; Amanda Cruz; Robin Kate Kelley
    JHEP reports : innovation in hepatology  , 102038-102038, 19, Sep. 2026 

MORE

Books etc

  1. 令和4年度改定薬学教育モデル・コア・カリキュラム準拠 疾患で学ぶ 病態・薬物治療 , 米田頼晃; 工藤正俊 , 炎症性腸疾患・大腸癌 , アークメディア, 東京 , 2025
  2. デュルバルマブ・トレメリムマブ併用療法による肝細胞癌治療 , 工藤正俊 , デュルバルマブ・トレメリムマブ併用療法の登場による肝細胞癌治療の今後の展開 , アークメディア, 東京 , Jan. 2025
  3. デュルバルマブ・トレメリムマブ併用療法による肝細胞癌治療 , 工藤正俊 , STRIDEレジメンによるsuper responderとその予測 , アークメディア, 東京 , Jan. 2025

MORE

Conference Activities & Talks

  1. Phase 3 LEAP-012 study of lenvatinib + pembrolizumab vs dual placebo with transarterial chemoembolization (TACE) for unresectable non-metastatic hepatocellular carcinoma: Long-term OS results , Llovet JM; Fin R.; Ren Z.; Guo Y.; Ogasawara S.; Kim JH; Li C.; Madoff DC; Vogel GA; Peng X.; Mody K.; Dubrovsky L.; Adelberg D.; Kudo M. , ESMO Congress 2026 , 26, Oct. 2026
  2. Liver function trajectory and post-progression outcomes in the Phase 3 EMERALD-3 study of tremelimumab (T) + durvalumab (D) ± lenvatinib (L) + transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible hepatocellular carcinoma (eeHCC) , Kudo M.; Abou-Alfa G.; Ren Z.; Heo J.; Erinjeri JP; Lencioni R.; Arai Y.; Penagos JFE; Lee IC; Lee JH; Wang F.; Jia W.; Mazzaferro V.; Lui AG; Roderburg C.; Akce M.; Tekumalla SH; Clark L.; Ali S.; Fan J. , ESMO Congress 2026 , 24, Oct. 2026
  3. Outcomes by baseline tumor burden using the 6-and-12 scores and the up-to-7 criteria in TALENTACE: Phase 3 study of on-demand TACE combined with atezolizumab +bevacizumab or on-demand TACE alone in patients with systemically untreated, unresectable HCC , Ogasawara S.; Dong J.; Kudo M.; Zhang H.; Li D.; Wang W.; Wang Y.; Wu F.; Du C.; Yin G.; Koga H.; Kodama T.; Morimoto M.; Tong L.; Shi Y.; Han G. , ESMO Congress 2026 , 23, Oct. 2026

MORE

MISC

  1. A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo plus bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results. , Masafumi Ikeda; Takeshi Terashima; Tatsuya Yamashita; Takuji Okusaka; Hiroshi Imaoka; Tomokazu Kawaoka; Satoshi Kobayashi; Sadahisa Ogasawara; Atsushi Hiraoka; Masahito Nakano; Fumio Nagashima; Rie Sugimoto; Michihisa Moriguchi; Yoshitaka Inaba; Satoru Shinoda; Makoto Ueno; Naoya Kato; Masatoshi Kudo; Junji Furuse; Hiroaki Nagano , JOURNAL OF CLINICAL ONCOLOGY , 43 , 4_SUPPL , Feb. 2025
  2. 複合免疫療法時代のシークエンシャル治療-HERITAGE試験から- , 淺岡良成; 淺岡良成; 建石良介; 山田康秀; 國土貴嗣; 斎藤明子; 長谷川潔; 坂元亨宇; 武冨紹信; 田中真二; 村上卓道; 吉満研吾; 黒崎雅之; 波多野悦朗; 松山裕; 工藤正俊; 國土典宏 , 日本肝がん分子標的治療研究会プログラム・抄録集 , 32nd , 2025
  3. 全国原発性肝癌追跡調査の機械学習により構築された3cm以下3個以下肝細胞癌の根治的治療法(肝切除術/ラジオ波焼灼術)選択を支援するAIアルゴリズム , 國土貴嗣; 山田康秀; 淺岡良成; 建石良介; 壁谷佳典; 鎌田亜美; 吉田澄人; 中村悠馬; 吉満研吾; 矢野博久; 村上卓道; 福本巧; 波多野悦朗; 島田光生; 加藤直也; 飯島尋子; 黒崎雅之; 坂元亨宇; 工藤正俊; 國土典宏 , 日本肝がん分子標的治療研究会プログラム・抄録集 , 32nd , 2025

MORE

Awards & Honors

  1. Apr. 2022, 日本消化器病学会学術賞受賞
  2. Nov. 2021, Highly Cited Researchers 2021 受賞(Clarivate Analytics:臨床医学部門）(日本人2名中1名)
  3. May. 2021, 日本超音波医学会 学会特別賞

MORE

Research Grants & Projects

  1. 日本学術振興会, 科学研究費助成事業, 肝内胆管がんの複合免疫療法抵抗性を規定するエピゲノム制御異常の解明 , 近畿大学
  2. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Evaluation of the current status of exposure and reduction measures in fluoroscopic endoscopic procedures (a nationwide multicenter study) , Kindai University
  3. 日本学術振興会, 科学研究費助成事業, 免疫チェックポイント阻害剤投与に伴う急速な腫瘍増大(HPD)の発症機序の解析 , 近畿大学

MORE